Priming therapy biotech emerges from stealth with seed funding — and on a hunt for partners
At Eigen Therapeutics, the goal is to make cancer treatment more effective. But not by making targeted drugs.
With $7 million in seed funding announced today, Eigen is a step closer to developing what are known as “priming therapies” that make cancer cells more visible to tumor-killing medicines, as well as building out a platform to design these therapies and discover potential new drug classes.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.